Overview
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Status:
Completed
Completed
Trial end date:
2006-05-01
2006-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.Phase:
Phase 2/Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Eyetech PharmaceuticalsCollaborator:
Pfizer
Criteria
Inclusion Criteria:Best corrected visual acuity in the study eye between 20/40 and 20/320 and better or equal
to 20/800 in the fellow eye.
Subfoveal CNV, secondary to AMD, w/ a total lesion size [including blood, scar/atrophy &
neovascularization] of less than or equal to 12 disc areas, of which at least 50% must be
active CNV.
Patients of either sex, aged greater than or equal to 50 years.
Exclusion Criteria:
Previous subfoveal thermal laser therapy. Any subfoveal scarring or atrophy & no more than
25% of the total lesion size may be made up of scarring or atrophy.
More than one prior PDT w/ Visudyne is not permitted. Pts may not have rec'd their 1st PDT
w/in less than 8 wks or more than 13 wks prior to the BSL angiography/photography for the
study.